[Pharmacodynamics of second generation sulfonylureas: dose-effect curve of gliclazide in type 2 diabetes mellitus].
Procacci
V
V
Giovine
A
A
Roberto
M G
MG
Di Reda
N
N
Lasorsa
G
G
Vendemiale
G
G
Stufano
N
N
Altomare
E
E
D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005907:Gliclazide / Q000493:pharmacokinetics*; D005947:Glucose / Q000494:pharmacology; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007328:Insulin / Q000097:blood; D008875:Middle Aged; D013453:Sulfonylurea Compounds / Q000493:pharmacokinetics* / Q000494:pharmacology
D001786:Blood Glucose; D002096:C-Peptide; D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds; C010969:gliquidone; D005907:Gliclazide; D005947:Glucose
Farmacodinamica delle solfaniluree di II generazione: curva dose effetto della gliclazide in diabetici tipo II.